<DOC>
	<DOCNO>NCT02983942</DOCNO>
	<brief_summary>Ketogenic diet show auxiliary effect treatment malignant tumor require high glucose consumption . This study design evaluate safety efficacy ketogenic diet adjunctive high dose methotrexate ( HD-MTX ) chemotherapy primary central nervous system lymphoma ( PCNSL ) .</brief_summary>
	<brief_title>Ketogenic Diet Adjunctive HD-MTX Chemotherapy Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>In pilot study primary central nervous system ( CNS ) lymphoma patient , ketogenic diet give adjunction standard HD-MTX chemotherapy interventional group ; standard HD-MTX give routine diet control group . The primary endpoint safety ketogenic diet PCNSL patient receive chemotherapy , secondary endpoint include rate complete remission , remission time , rate tumor relapse overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . Age 1870 2 . Histopathologically confirm PCNSL 3 . No systemic involvement 4 . Ability willingness sign inform consent 5 . Normal liver kidney function 6 . Karnofsky Performance Score 60 1 . Any systemic involvement tumor 2 . Systemic illness medical condition may pose additional risk , include cardiac , metabolic endocrine disorder ; incompensated renal liver disfunction ; history renal calculus , hyperuricemia , hyper calcemia , mitochondrial disease , know disorder fatty acid metabolism , porphyria , carnitine deficiency pancreatitis 3 . Uncontrolled hyperlipidemia hyperglycemia 4 . Human immunodeficiency virus positive , hepatitis C positive 5 . Pregnancy breastfeed 6 . Inability unwillingness give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ketogenic diet</keyword>
	<keyword>Primary Central Nervous System Lymphoma</keyword>
	<keyword>chemotherapy</keyword>
</DOC>